Goldman Sachs’s Timber Pharmaceuticals, Inc. TMBR Stock Holding History

Goldman Sachs’s Portfolio TMBR Stock Details TMBR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-484	Closed	-$22K	–	6836
2021 Q3	$22K	Buy	+484	New	+$23.7K	﹤0.01%	6146
2019 Q3	–	Sell	-23	Closed	-$8K	–	5455
2019 Q2	$8K	Buy	+23	New	+$17.9K	﹤0.01%	5082
2018 Q4	–	Sell	-11	Closed	-$32K	–	5811
2018 Q3	$32K	Buy	+11	New	+$31.8K	﹤0.01%	5364

Other funds holding TMBR

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Goldman Sachs's TMBR Position: Q4 2021 in Review

Goldman Sachs sold out of Timber Pharmaceuticals, Inc. (TMBR) in Q4 2021, closing a stake of 484 shares — an estimated $22K sold.

Goldman Sachs first reported a position in TMBR in Q3 2018 and held it in 3 quarters. The position peaked at $32K in Q3 2018. 17 funds tracked by Wall St. Rank hold TMBR as of Q4 2021.

Goldman Sachs reported no remaining Timber Pharmaceuticals, Inc. position as of Q4 2021 after selling out during the quarter.
Goldman Sachs sold 484 Timber Pharmaceuticals, Inc. shares in Q4 2021, an estimated $22K.
Goldman Sachs first reported a position in Timber Pharmaceuticals, Inc. in Q3 2018 and held it in 3 quarters.
Goldman Sachs's Timber Pharmaceuticals, Inc. position peaked at $32K in Q3 2018.
17 funds tracked by Wall St. Rank held Timber Pharmaceuticals, Inc. as of Q4 2021.

Based on Goldman Sachs's 13F filing for Q4 2021, filed 14 Feb 2022.